Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease
批准号:
10046281
负责人:
HUIPING Rose ZHOU
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-10-01 至 2021-09-30
关键词:
AffectAlkaloidsAnimal ModelAnti-Inflammatory AgentsApoptosisAsiaBerberineBile AcidsCholesterolCholesterol HomeostasisClinicClinical TrialsCommunicable DiseasesComplementary and alternative medicineDevelopmentDiseaseDisease ProgressionDyslipidemiasEpithelial CellsEquilibriumFDA approvedFatty acid glycerol estersFutureHealthHepaticHepatocyteHuR proteinHypoglycemiaImmuneImmune responseInflammationInflammatoryInflammatory ResponseInsulin ResistanceInterleukin-6Intestinal permeabilityIsoquinolinesKnock-outLeadLinkLipidsLipopolysaccharidesLiver diseasesMediatingMedicinal HerbsMedicineMetabolicMetabolic DiseasesMetabolic syndromeMicroRNAsModelingMolecularNatural ProductsNucleotidesPathogenesisPharmaceutical PreparationsPharmacologyPlantsPropertyProteinsRNA-Binding ProteinsReportingResearchRoleSaturated Fatty AcidsSignal PathwayTNF geneTestingTherapeutic AgentsTherapeutic EffectUntranslated RNAVeteransbasebile acid metabolismbiological adaptation to stresschronic liver diseaseclinical developmentcytokineendoplasmic reticulum stressgut microbiotain vivointestinal barrierintestinal epitheliumlipid metabolismlong chain fatty acidmacrophagemetabolic endotoxemiamilitary veterannon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeutic interventionprotective effectresponsesystemic inflammatory responsetherapeutic evaluationtherapeutically effectivetranscription factor CHOPwestern diet
中文摘要
非酒精性脂肪性肝病(NAFLD)已成为最常见的慢性肝病,尤其是
在美国退伍军人中。非酒精性脂肪肝与炎症、胰岛素抵抗、血脂异常和
代谢综合征。NAFLD和非酒精性脂肪性肝炎(NASH)研究的最新进展表明
肠道微生物区系通过影响宿主代谢平衡在疾病进展中发挥重要作用
和免疫反应。“代谢性内毒素血症”与循环内毒素水平升高
(脂蛋白)由于肠屏障功能的破坏和游离长链脂肪酸(FFA)与
刺激全身炎症和胰岛素抵抗,这两者都与
非酒精性脂肪肝的发展和进展。尽管脂多糖/游离脂肪酸诱导肝损伤的机制
脂毒性仍不完全清楚,内毒素/游离脂肪酸诱导炎性细胞因子如肿瘤坏死因子-1的表达。
与激活内质网应激信号通路,称为未折叠蛋白
回应(普遍定期审议)是主要的贡献者。此外,微小RNA(MiR)、小非编码RNA(~22
核苷酸),最近被发现是脂类和胆固醇代谢的有效调节剂。改建
In miR的表达也与内毒素/游离脂肪酸诱导的炎症反应、肝脏脂肪毒性和
胰岛素抵抗与非酒精性脂肪性肝病的临床进展异喹啉黄连素(BBR)
从许多中草药中分离出来的生物碱,已被用于治疗各种感染性疾病超过
在亚洲已经有3000年的历史了。大量研究表明,BBR具有多种药理活性,包括
具有抗炎、降血糖、降脂作用。重要的是,BBR代表了一种新的胆固醇-
通过与目前的他汀类药物治疗不同的独特机制降低药物。这些研究强烈地
提示BBR是治疗NAFLD/NASH的一种有前途的天然药物。然而,分子
BBR的抗炎和降脂作用的机制仍未完全确定。
我们已经证明,补肾活血方通过调节内质网应激介导的肿瘤坏死因子-和IL-6的表达来抑制
巨噬细胞中的RNA结合蛋白(RBP)Hur。MIR研究的最新进展已经确定
作为炎症、脂肪代谢和代谢紊乱的主要调节因子的MIR的特异性小组,如
如miR-155、miR-125a-5p、miR-33、miR-34a和miR-122。此外,据报道,BBR施加了
调节肠道微生物区系对高脂饮食诱导的NAFLD/NASH的保护作用
和胆汁酸代谢。我们的初步研究还表明,1)BBR显著抑制了WD诱导的
动物模型的肝脏脂质堆积和全身炎症;2)BBR抑制FFA诱导的ER
3)BBR抑制FFA诱导的小鼠肝细胞miR-34a表达。
肝细胞和内毒素诱导的巨噬细胞miR-125a-5p的表达;4)miR-34a的表达
C/EBP同源蛋白(CHOP)的表达显著下调,CHOP是内质网应激介导的主要参与者
细胞凋亡)敲除(CHOP-/-)原代肝细胞;5)BBR显著降低WD诱导的
6)内质网应激和内毒素对肠上皮细胞更新的抑制作用
通过删除印章而获救。基于这些观察,我们假设BBR抑制WD-
通过抑制内质网应激和炎症反应诱导肝脏脂肪毒性。以下两个具体内容
为了检验这一假说,我们提出了目标。目标1:确定BBR抑制BBR的机制
脂多糖/游离脂肪酸诱导的内质网应激和肝细胞和巨噬细胞的炎症反应;目的#2:
明确BBR抑制WD诱导的肝脂毒性的机制,并进一步检验其治疗作用
在一种新的体内NAFLD/NASH模型中,BBR对WD诱导的肝脏脂肪毒性的影响。
英文摘要
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease, especially
among US veterans. NAFLD is critically linked to inflammation, insulin resistance, dyslipidemia, and the
metabolic syndrome. Recent advances in NAFLD and non-alcoholic steatohepatitis (NASH) studies indicate
that gut microbiota exerts a significant role in the disease progression by affecting host metabolic balance
and immune response. The “metabolic endotoxemia” and elevated circulating levels of lipopolysaccharide
(LPS) due to disruption of intestinal barrier function and free long chain fatty acids (FFA) are implicated in the
stimulation of systemic inflammation and insulin resistance, both of which are positively correlated with the
development and progression of NAFLD. Although the mechanism by which LPS/FFA induce hepatic
lipotoxicity is still not fully understood, LPS/FFA-induced expression of inflammatory cytokines such as TNF-
and activation of the endoplasmic reticulum (ER) stress signaling pathway, known as the unfolded protein
response (UPR), are major contributors. Furthermore, micro-RNAs (miR), small noncoding RNAs (~22
nucleotides), have recently been found to be potent regulators of lipid and cholesterol metabolism. Alterations
in miR expression have also been linked to LPS/FFA-induced inflammatory response, hepatic lipotoxicity and
insulin resistance as well as disease progression of NAFLD in the clinic. Berberine (BBR), an isoquinoline
alkaloid isolated from many medicinal herbs, has been used to treat various infectious disorders for more than
3,000 years in Asia. Numerous studies have shown that BBR has various pharmacological activities including
anti-inflammatory, hypoglycemic and lipid-lowering effects. Importantly, BBR represents a novel cholesterol-
lowering drug through a unique mechanism distinct from the current statin therapy. These studies strongly
indicate that BBR is a promising natural therapeutic agent for NAFLD/NASH. However, the molecular
mechanisms underlying BBR’s anti-inflammatory and lipid-lowering properties remain to be fully identified.
We have demonstrated that BBR inhibits ER stress-mediated TNF- and IL-6 expression through regulating
the RNA-binding protein (RBP) HuR in macrophages. Recent advances in miR research have identified
specific panels of miRs as major regulators of inflammation, lipid metabolism and metabolic disorders, such
as miR-155, miR-125a-5p, miR-33, miR-34a, and miR-122. In addition, it has been reported that BBR exerted
protective effects against high fat Western diet (WD)-induced NAFLD/NASH via modulating gut microbiota
and bile acid metabolism. Our preliminary studies also indicate that 1) BBR significantly inhibited WD-induced
hepatic lipid accumulation and systemic inflammation in animal models; 2) BBR inhibited FFA-induced ER
stress and lipid accumulation in hepatocytes; 3) BBR inhibited FFA-induced miR-34a expression in
hepatocytes and LPS-induced miR-125a-5p expression in macrophages; 4) The expression of miR-34a was
significantly down-regulated in C/EBP homologous protein (CHOP, a major player of ER stress-mediated
apoptosis) knock out (CHOP-/-) primary hepatocytes; 5) BBR significantly reduced WD-induced increase of
intestinal permeability; 6) ER stress- and LPS-induced suppression of intestinal epithelial cell renewal was
rescued by deletion of the CHOP. Based on these observations, we HYPOTHESIZE that BBR inhibits WD-
induced hepatic lipotoxicity by inhibiting ER stress and inflammatory response. The following two specific
aims are proposed to test this hypothesis. Aim #1:To determine the mechanism by which BBR inhibits
LPS/FFA-induced ER stress and the inflammatory response in hepatocytes and macrophages; Aim #2: To
identify the mechanism by which BBR inhibits WD-induced hepatic lipotoxicity and further test the therapeutic
effect of BBR on WD-induced hepatic lipotoxicity in a novel in vivo NAFLD/NASH model.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.livres.2019.02.003
发表时间:
2019-03-01
期刊:
Liver research
影响因子:
--
作者:
[Kwong, Eric K, Zhou, Huiping]
通讯作者:
Zhou, Huiping
DOI:
10.3390/cells11081374
发表时间:
2022-04-18
期刊:
Cells
影响因子:
6
作者:
[Way GW, Jackson KG, Muscu SR, Zhou H]
通讯作者:
Zhou H
DOI:
10.3390/cells10112806
发表时间:
2021-10-20
期刊:
Cells
影响因子:
6
作者:
[Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H]
通讯作者:
Zhou H
DOI:
10.3390/cells12050792
发表时间:
2023-03-02
期刊:
Cells
影响因子:
6
作者:
[]
通讯作者:
Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
丁酸钠通过上调肝脏 GLP-1R 表达来减少高脂饮食诱导的非酒精性脂肪性肝炎
DOI:
10.1038/s12276-018-0183-1
发表时间:
2018-12-03
期刊:
Experimental & molecular medicine
影响因子:
12.8
作者:
[Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, Zhou H, Fan JG]
通讯作者:
Fan JG
共 10 条
Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)
-
批准号:10474084
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:HUIPING Rose ZHOU
-
依托单位:
The ShEEP request for NanoString GeoMx Digital Spatial Profiling and nCounter MAX Complete System
-
批准号:10161359
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:HUIPING Rose ZHOU
-
依托单位:
The ShEEP request for Waters Xevo TQ-XS Liquid Chromatography Mass Spectrometer System
-
批准号:9792705
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:HUIPING Rose ZHOU
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10293559
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:HUIPING Rose ZHOU
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10515313
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:HUIPING Rose ZHOU
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10047294
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity
-
批准号:8331653
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity
-
批准号:8510387
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Impact of Alcohol on HIV Protease Inhibitor-induced ER Stress and Lipotoxicity
-
批准号:8698297
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine
-
批准号:7809454
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2007
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine
-
批准号:7415191
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2007
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine
-
批准号:7281496
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2007
-
负责人:HUIPING Rose ZHOU
-
依托单位:
Prevent HIV protease inhibitor-induced atherosclerosis by Berberine
-
批准号:7623483
-
项目类别:
-
资助金额:$35.93万
-
财政年份:2007
-
负责人:HUIPING Rose ZHOU
-
依托单位:
HIV Protease Inhibitors, the Unfolded Protein Response and Atherosclerosis
-
批准号:7162411
-
项目类别:
-
资助金额:$18.63万
-
财政年份:2006
-
负责人:HUIPING Rose ZHOU
-
依托单位:
HIV Protease Inhibitors, the Unfolded Protein Response and Atherosclerosis
-
批准号:7268024
-
项目类别:
-
资助金额:$21.7万
-
财政年份:2006
-
负责人:HUIPING Rose ZHOU
-
依托单位:
国内基金
海外基金
Iboga alkaloids骨架导向的不对称串联反应构建吖庚环并[4,5-b]吲哚及其在全合成中的应用
-
批准号:21801032
-
项目类别:青年科学基金项目
-
资助金额:26.0万元
-
批准年份:2018
-
负责人:陈惠渝
-
依托单位: